Market Update | BHP, CSL, Cochlear, Pro Medicus, Hub24
Market Update | BHP, CSL, Cochlear, Pro Medicus, Hub24
About this video
BHP (ASX:BHP) has reported better than expected underlying profit for the full-year - thanks to higher copper prices, with the red metal overtaking iron ore as BHP's biggest earnings driver. Underlying profit rose 30% to 13-point-2 billion US dollars with revenue up 15% to just shy of 59 billion US dollars. CEO Brandon Craig said copper is the engine driving BHP's growth with copper prices climbing to record highs above $14,000 a tonne this year, triggered by the rapid pace of energy-hungry AI data centre buildout and the global shift toward cleaner power. BHP announced a final dividend of 99 US cents per share, bringing in the full-year distribution to US$1.72, the highest in four years. BHP also confirmed a fatal injury last month and said it continues to further improve safety.
CSL (ASX:CSL) expects to deliver a 5 per cent increase in underlying profit growth in FY 2027 but warned revenues will be flat due to a sharp fall in sales for its Vifor kidney and iron deficiency business. FY26 brought a 2per cent fall in underlying earnings to $4.4 billion in line with its downgraded forecasts, and a net loss of $2.6B US - or $3.65 Aussie dollars due to restructuring costs and impairments. Revenue fell 1 per cent to $US15.8 billion - slightly higher than forecast. While CSL is forecasting mid-single digit revenue growth for its core blood plasma Behring business this year, declining US immunisation rates will weigh on its Seqirus vaccines arm. CSL blames the forecast 25% drop in revenue for Vifor is to competition in iron products and changes in Medicare payments.
Cochlear (ASX:COH) has hit the upper end of its revised guidance which shocked the market back in April, delivering full-year sales revenue of 2.3 billion dollars, up 2 percent in constant currency terms. For FY27, Cochlear expects low single-digit revenue growth and underlying net profit of 330 to 350 million dollars. That's an improvement on FY26 in which Cochlear delivered underlying net profit totalling 322 million dollars, down 22 percent from the prior year. Cochlear says it will continue to cut fixed costs to improve margins and allow for R&D.
Pro Medicus (ASX:PME) has reported a 32.5% jump in net profit to $154.5 million on a constant-currency basis, ahead of its own guidance. Revenue rose 28.4% to $273.5 million, while margins improved by 90 basis points, supporting the lift in profit. The company also recorded a record number of client renewals, with most contracts carrying higher minimums and all featuring increased transaction fees. Pro Medicus said the full benefit of 16 implementations completed in FY26 will flow through from FY27 and beyond. Pro Medicus declared a fully franked final dividend of 37 cents per share.
Investment platform HUB24 (ASX:HUB) has posted a record FY26, with net inflows jumping 20% to $18.9 billion. Funds under administration also rose 20% to $164.3 billion, while platform FUA climbed 24% to $139.5 billion. Net profit surged 51% to $120.2 million, ahead of expectations, on a 23% lift in revenue to $501.1 million. HUB24 declared a fully franked final dividend of 42 cents per share and ranked first for net inflows for a tenth consecutive quarter. Looking ahead, it’s targeting $186–200 billion in platform FUA by FY28.